Does orphan drug legislation really answer the needs of patients?

The Lancet

Volumn 371, Issue 9629, 2008, Pages 2041-2044

  Haffner, Marlene E ^a   Torrent Farnell, Josep ^a   Maher, Paul D ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; IMIGLUCERASE; ORPHAN DRUG; PEGADEMASE; RECOMBINANT ERYTHROPOIETIN;

BIOTECHNOLOGY; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; ENZYME REPLACEMENT; GAUCHER DISEASE; INFECTION; METABOLIC DISORDER; PATIENT CARE; PHARMACOGENOMICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROFIT; RARE DISEASE; REVIEW;

EID: 44849139068     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60873-9     Document Type: Review

References (36)

1. NORD. Letter to FDA Commisioner: Mark McClellan. Medicare program. Competitive acquisition of outpatient drugs and biologicals under part B interim rule (Sept 6, 2005). http://www.rarediseases.org/news/policy/policy (accessed April 3, 2006).
2. Office of Orphan Products Development. List of orphan designations and approvals. http://www.fda.gov/orphan/designat/list.htm (accessed Jan 18, 2007).
3. Rados C. Orphan products: hope for people with rare diseases. FDA Consumer Mag 37 (2003) 10-15
4. Milne C. Orphan products: pain relief for clinical development headaches. Nature Biotechnol 20 (2002) 780-784
5. The Tufts Center for the Study of Drug Development. Pegs cost of a new prescription medicine at $802 million (2001). http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=6 (accessed April 24, 2006).
6. FDA. Challenge and opportunity on the critical path to new medical products. White paper (March 2004). http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html (accessed April 1, 2006).
7. Loughnot D. Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses?. Am J Law Med 31 (2005) 365-380
8. Love J. Brief note on the abuse of orphan drug programs in creating monopolies (January 5th 1999). http://www.cptech.org/ip/health/orphan/#Brief%20note%20on%20the%20abuse% 20of%20Orphan%20Drug%20programs%20in%20creating%20monopolies (accessed April 3, 2006).
9. Maeder T. The orphan drug backlash. Sci Am 288 (2003) 80-88
10. Anand G. Why Genzyme can charge so much for Cerezyme. Wall Street J (Nov 16, 2005)
11. Futerman A., Sussman J., Horowitz M., Silman I., and Ziniran A. New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 25 (2004) 147-245
12. Smith A. From orphan to blockbuster? Biotechs lead the way in getting orphan drugs to market, and sometimes they actually make money. http://money.cnn.com/2005/07/08/news/midcaps/orphan/index.htm (accessed April 3, 2006).
13. Cheung R., Cohen J., and Illingworth P. Orphan drug policies: implications for the United States, Canada and developing countries. Health Law J 12 (2004) 183-200
14. Arnon S. Creation and development of the public service orphan drug human botulism immune globuli. Pediatrics 119 (2007) 785-789
15. FDA. NDA 20-785 FDA: approval letter (July 16, 1998). http://www.fda.gov/cder/foi/appletter/1998/20785ltr.pdf (accessed May, 2007).
16. International Myeloma Foundation. The International Myeloma Foundation applauds FDA approval of thalomid for myeloma patients (2006). http://www.myeloma.org/main.jsp?source=link&source_link_id=2185& type=article&tab_id=1&menu_id=0&id=1831 (accessed May 20, 2008)
17. Joppi R., Bertele V., and Garatinni S. Orphan drug development is progressing too slowly. B J Clin Pathol 61 (2006) 355-360
18. Department of Health and Human Services. The Orphan Drug Act: implementation and impact (2001), Office of Inspector General, Department of Health and Human Services, San Francisco, CA
19. Center for Drug Evaluation and Research, FDA. Electronic orange book, application 019818, pegademase, approved March 21,1990. http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No= 019818&TABLE1=OB_Rx (accessed April 12, 2006).
20. Center for Drug Evaluation and Research, FDA. Approval letter for application nember 21-232, Orfadin (Jan 18, 2002). www.fda.gov/cder/foi/nda/2002/21-232_ORFADIN_Approv.pdf (accessed Jan 25, 2007).
21. Scott CE. The genetic tyrosinemias. Am J Med Genet Part C Semin Med Genet 142C: 121-26.
22. Hershfield M., Buckley R., and Greenberg M. Treatment of adenosine demainase deficiency with polyethylene glycol modified adenosine deaminase. N Engl J Med 316 (1987) 589-596
23. Anand G. As biotech drug prices surge, US is hunting for a solution. Wall Street J (Dec 28, 2005) A1
24. Maher P., and Haffner M. Orphan drug designation and pharmacogenomics: options and opportunities. Biodrugs 20 (2006) 71-79
25. WHO. Report on infectious diseases: removing obstacles to healthy development (1999), World Health Organization, Geneva
26. FDA. Rifampin designated for antituberculosis treatment where use of the oral form of the drug is not feasible. on 12/9/1985, Approved to market 5/25/1989. http://www.fda.gov/orphan/designat/list.htm (accessed Nov 16, 2006).
27. FDA. Rifampin in combination with isoniazid, pyrazinamide desingated for short-course treatment of tuberculosis. on 9/12/1985. Approved to market 5/31/1994. http://www.fda.gov/orphan/designat/list.htm (accessed Nov 16, 2006).
28. FDA. Rifapentine designated for treatment of pulmonary tuberculosis on 6/9/1995. Approved to market 6/22/1998. http://www.fda.gov/orphan/designat/list.htm (accessed Dec 15, 2006).
29. FDA. Halofantrine designated for treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax on 11/4/1991. Approved to market 7/24/1992. http://www.fda.gov/orphan/designat/list.htm (accessed Dec 11, 2006).
30. FDA. Mefloquine HCl designated for treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax on 4/13/1988. Approved to market 5/2/1989. http://www.fda.gov/orphan/designat/list.htm (accessed Jan 25, 2007).
31. FDA. Quinine sulfate designated for treatment of uncomplicated Plasmodium falciparum malaria on 6/3/2004. Approved to market 8/12/2005. http://www.fda.gov/orphan/designat/list.htm (accessed Dec 11, 2006).
32. Simon H. Orphan drugs for the third world. Ann Intern Med 95 (1981) 231-232
33. Broder S., Hoffman S., and Hotez P. Cures for the third world's problems. EMBO Rep 3 (2002) 806-812
34. Hershfield M., and Finkelberg Z. ADA deficiency treatment. Science 246 (1989) 1375
35. FDA. Cumulative list of designated approved orphan products. http://www.fda.gov/orphan/designat/allap.rtf (accessed May 24, 2006).
36. Pegasys (peginterferon alpha 2a) package insert. Hoffman-La Roche. http://www.fda.gov/cder/foi/label/2002/pegihof101602LB.htm (accessed May 24, 2006).